- Home
- SENS vs PROK Comparison
SENS vs PROK Comparison
Compare SENS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENS | PROK |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.5M | 269.7M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SENS | PROK |
|---|---|---|
| Price | $6.77 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $18.38 | $7.40 |
| AVG Volume (30 Days) | 301.7K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,389,000.00 | $893,000.00 |
| Revenue This Year | $74.15 | N/A |
| Revenue Next Year | $58.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.85 | ★ 1075.00 |
| 52 Week Low | $0.41 | $0.54 |
| 52 Week High | $8.75 | $7.13 |
Technical Indicators
Market Signals| Indicator | SENS | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 59.52 |
| Support Level | $6.62 | $2.09 |
| Resistance Level | $6.87 | $2.58 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 72.35 | 99.17 |
Price Performance
Historical ComparisonAbout SENS Senseonics Holdings Inc.
Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.